Cell and Gene Outsourcing

  1. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma. 

  2. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

  3. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

    In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

  4. Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service 11/17/2021

    The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing.

  5. Meet The Experts: Part 2 - Raman Spectroscopy 5/1/2023

    Watch part 2 of this 4-part interview series to explore Raman spectroscopy, one of the main PAT tools for monitoring bioprocess CQAs and CPPs, with expert Fabien Caron.

  6. Managing Risks In Injectable Drug Delivery 3/13/2025

    Gain insights pertinent to efficient and effective drug development. Understand and execute a risked-based critical thinking approach related to injectable drug packaging and delivery.

  7. Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity

    Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.

  8. PEI And Non-PEI Transfection Solutions For High Titers And Production 9/2/2025

    Discover optimized AAV production with polyethylenimine (PEI) and non-polyethylenimine transfection solutions that are designed to boost titers and streamline scalability.

  9. Cryopreservation Best Practices For Cell & Gene Therapy Source Material 2/26/2024

    Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.

  10. A Robust And Scalable Suspension Platform For AAV Manufacturing

    Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.